Reflection on design and testing of pancreatic alpha-amylase inhibitors: An in silico comparison between rat and rabbit enzyme models

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Khalil Moghaddam, Shiva ^a   Ebrahim Habibi, Azadeh ^b   Pasalar, Parvin ^c   Yaghmaei, Parichehreh ^a   Hayati Roodbari, Nasim ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amylase inhibitor; Docking; Homology modeling; Rabbit alpha amylase; Rat alpha amylase

Indexed keywords

AMYLASE INHIBITOR; PANCREATIC ALPHA AMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SCREENING; ENZYME STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; RABBIT; RAT;

EID: 84874596297     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-77     Document Type: Article

References (32)

1. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. Preuss HG, J Am Coll Nutr 2009 28 266 276 20150600
2. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Tundis R, Loizzo MR, Menichini F, Mini Rev Med Chem 2010 10 315 331 10.2174/ 138955710791331007 20470247
3. The search for novel human pancreatic alpha-amylase inhibitors: high-throughput screening of terrestrial and marine natural product extracts. Tarling CA, Woods K, Zhang R, Brastianos HC, Brayer GD, Andersen RJ, Withers SG, Chembiochem 2008 9 433 438 10.1002/cbic.200700470 18214874
4. Characterization and functional properties of the alpha-amylase inhibitor (alpha-AI) from kidney bean (Phaseolus vulgaris) seeds. Le Berre-Anton V, Bompard-Gilles C, Payan F, Rouge P, Biochim Biophys Acta 1997 1343 31 40 10.1016/S0167-4838(97)00100-3 9428656 (Pubitemid 28015477)
5. In vitro and in vivo anti-hyperglycemic effects of omija (Schizandra chinensis) Fruit. Jo SH, Ha KS, Moon KS, Lee OH, Jang HD, Kwon YI, Int J Mol Sci 2011 12 1359 1370 10.3390/ijms12021359 21541063
6. Trans-chalcone: a novel small molecule inhibitor of mammalian alpha-amylase. Najafian M, Ebrahim-Habibi A, Hezareh N, Yaghmaei P, Parivar K, Larijani B, Mol Biol Rep 2011 38 1617 1620 10.1007/s11033-010-0271-3 20857221
7. Chestnut astringent skin extract, an alpha-amylase inhibitor, retards carbohydrate absorption in rats and humans. Tsujita T, Takaku T, Suzuki T, J Nutr Sci Vitaminol (Tokyo) 2008 54 82 88 10.3177/jnsv.54.82 (Pubitemid 351413107)
8. Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus. Layer P, Rizza RA, Zinsmeister AR, Carlson GL, DiMagno EP, Mayo Clin Proc 1986 61 442 447 10.1016/S0025-6196(12)61978-8 2423813 (Pubitemid 16100857)
9. Core structure of flavonoids precursor as an antihyperglycemic and antihyperlipidemic agent: an in vivo study in rats. Najafian M, Ebrahim-Habibi A, Yaghmaei P, Parivar K, Larijani B, Acta Biochim Pol 2010 57 553 560 21060897
10. Gastrointestinal and metabolic effects of amylase inhibition in diabetics. Boivin M, Flourie B, Rizza RA, Go VL, DiMagno EP, Gastroenterology 1988 94 387 394 2446948 (Pubitemid 18054774)
11. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Aoki K, Muraoka T, Ito Y, Togashi Y, Terauchi Y, Intern Med 2010 49 1085 1087 10.2169/internalmedicine.49.3218 20558922
12. The use of animal models in the study of diabetes mellitus. Chatzigeorgiou A, Halapas A, Kalafatakis K, Kamper E, In Vivo 2009 23 245 258 19414410
13. Clustal W and Clustal X version 2.0. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al. Bioinformatics 2007 23 2947 2948 10.1093/bioinformatics/btm404 17846036 (Pubitemid 350162903)
14. ModBase, a database of annotated comparative protein structure models, and associated resources. Pieper U, Webb BM, Barkan DT, Schneidman-Duhovny D, Schlessinger A, Braberg H, Yang Z, Meng EC, Pettersen EF, Huang CC, et al. Nucleic Acids Res 2011 39 465 D474 10.1093/nar/gkq1091 21097780
15. Comparative protein modelling by satisfaction of spatial restraints. Sali A, Blundell TL, J Mol Biol 1993 234 779 815 10.1006/jmbi.1993.1626 8254673 (Pubitemid 24007801)
16. Comparative modeling for protein structure prediction. Ginalski K, Curr Opin Struct Biol 2006 16 172 177 10.1016/j.sbi.2006.02.003 16510277
17. MolProbity: all-atom structure validation for macromolecular crystallography. Chen VB, 3rd Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC, Acta Crystallogr D Biol Crystallogr 2010 66 12 21 20057044
18. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Trott O, Olson AJ, J Comput Chem 2010 31 455 461 19499576
19. Rapid comparison of protein structures. McLachlan AD, Acta Crystallogr A: Crystal Phys, Diffraction, Theor and Gen Crystallography 1982 38 871 873 10.1107/S0567739482001806
20. Modeling regionalized volumetric differences in protein-ligand binding cavities. Chen BY, Bandyopadhyay S, Proteome Sci 2012 10 Suppl 1 6 10.1186/1477-5956-10-S1-S6 22759583
21. Analysis of binding site similarity, small-molecule similarity and experimental binding profiles in the human cytosolic sulfotransferase family. Najmanovich RJ, Allali-Hassani A, Morris RJ, Dombrovsky L, Pan PW, Vedadi M, Plotnikov AN, Edwards A, Arrowsmith C, Thornton JM, Bioinformatics 2007 23 104 e109 10.1093/bioinformatics/btl292 17237076 (Pubitemid 46189643)
22. Enzyme-catalyzed condensation reaction in a mammalian alpha-amylase. High-resolution structural analysis of an enzyme-inhibitor complex. Qian M, Nahoum V, Bonicel J, Bischoff H, Henrissat B, Payan F, Biochemistry 2001 40 7700 7709 10.1021/bi0102050 11412124 (Pubitemid 32578034)
23. Stereochemistry of polypeptide chain configurations. Ramachandran GN, Ramakrishnan C, Sasisekharan V, J Mol Biol 1963 7 95 99 10.1016/S0022-2836(63) 80023-6 13990617
24. The structure of human pancreatic alpha-amylase at 1.8 A resolution and comparisons with related enzymes. Brayer GD, Luo Y, Withers SG, Protein Sci 1995 4 1730 1742 10.1002/pro.5560040908 8528071
25. Subsite mapping of the human pancreatic alpha-amylase active site through structural, kinetic, and mutagenesis techniques. Brayer GD, Sidhu G, Maurus R, Rydberg EH, Braun C, Wang Y, Nguyen NT, Overall CM, Withers SG, Biochemistry 2000 39 4778 4791 10.1021/bi9921182 10769135 (Pubitemid 30225343)
26. Structural and mechanistic studies of chloride induced activation of human pancreatic alpha-amylase. Maurus R, Begum A, Kuo HH, Racaza A, Numao S, Andersen C, Tams JW, Vind J, Overall CM, Withers SG, Brayer GD, Protein Sci 2005 14 743 755 10.1110/ps.041079305 15722449 (Pubitemid 40283913)
27. Structural similarities and evolutionary relationships in chloride-dependent alpha-amylases. D'Amico S, Gerday C, Feller G, Gene 2000 253 95 105 10.1016/S0378-1119(00)00229-8 10925206 (Pubitemid 30488890)
28. Structures of human pancreatic alpha-amylase in complex with acarviostatins: Implications for drug design against type II diabetes. Qin X, Ren L, Yang X, Bai F, Wang L, Geng P, Bai G, Shen Y, J Struct Biol 2011 174 196 202 10.1016/j.jsb.2010.11.020 21111049
29. Enzymatic synthesis of a new inhibitor of alpha-amylases: acarviosinyl-isomaltosyl-spiro-thiohydantoin. Kandra L, Remenyik J, Batta G, Somsak L, Gyemant G, Park KH, Carbohydr Res 2005 340 1311 1317 10.1016/j.carres.2005.03.003 15854600 (Pubitemid 40602285)
30. Variability in docking success rates due to dataset preparation. Corbeil CR, Williams CI, Labute P, J Comput-aided Mol design 2012 26 775 786 10.1007/s10822-012-9570-1
31. Molecular dynamics simulation studies of betulinic acid with human serum albumin. Malleda C, Ahalawat N, Gokara M, Subramanyam R, J Mol Model 2011 18 2589 9257 22076062
32. In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease. Ul-Haq Z, Khan W, Kalsoom S, Ansari FL, Theor Biol Med Model 2010 7 22 10.1186/1742-4682-7-22 20550720